(The Center Square) – Top 10 pharmaceutical industry giant Novartis says it will spend a portion of its $23 billion American investment in manufacturing, research and development in a 56,200 square foot facility in North Carolina.
The fifth facility at three sites in the state will be in the Research Triangle Park area, in the community of Morrisville. Active pharmaceutical ingredient manufacturing for solid dosage tablets, capsules and RNA therapeutics will be the focus.
“Last year we committed to adding seven new facilities in the U.S., and today we finalize our plans to expand our U.S. manufacturing and R&D footprint in the U.S.,” said Vas Narasimhan, CEO of Novartis. “By building a connected, end-to-end footprint, we are strengthening our ability to locally develop, produce, and deliver medicines at scale, enabling timely access to innovation for patients in the U.S.”
Novartis operations are in the counties of Durham and Wake where Research Triangle Park sprawls. The Swiss drugmaker in November said a $771 million plan for pharmaceutical manufacturing operations in the state would create 700 new jobs by the end of 2030.
Novartis’ first quarter had net sales of $13.1 billion and core net income of $3.79 billion.
